Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Published reports on the safety and efficacy of extreme hypofactionated radiation therapy (stereotactic body radiation therapy or SBRT, a.k.a. CyberKnife radiation therapy) have, to date, come from just a couple of key centers.
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: CyberKnife, outcome, SBRT, stereotactic body radiation therapy | 2 Comments »
A multi-institutional “Registry for Prostate Cancer Radiosurgery” (RPCR) was initially set up in July 2010 to track clinical and functional outcomes of men with localized prostate cancer treated with the CyberKnife stereotactic body radiation therapy system (SBRT) at academic and community-based centers throughout the U.S.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CyberKnife, outcome, registry, stereotactic body radiation therapy | 3 Comments »
Over the past 20 years there has been an explosion in the different ways that we use varied types of external beam radiation therapy for the treatment of localized and locally advanced forms of prostate cancer. Where is the newly diagnosed patient able to find a good, basic introduction?
Filed under: Management, Treatment | Tagged: 3D-CRT, CyberKnife, EBRT, external beam radiation therapy, IGRT, IMRT, introduction, PBRT, SBRT, TomoTherapy | 2 Comments »
Most published data on the use of stereotactic body radiation therapy (SBRT; CyberKnife radiation therapy) has been based on a total radiation dose of 32 to 38 Gy delivered in a series of four or five sessions — as compared to the delivery of more like 75 to 80 Gy using intensity-modulated radiation (IMRT) and [...]
Filed under: Management, Treatment | Tagged: CyberKnife, dose, escalation, outcome, SBRT, stereotactic body radiation therapy | 2 Comments »
In an announcement this morning that will shake up the innovation end of the cancer radiotherapy business, Accuray, Inc. (which makes and markets the CyberKnife system for stereotactic body radiation therapy) has agreed to acquire TomoTherapy, Inc. (which integrates CT imaging with conformal radiation therapy).
Filed under: Uncategorized | Tagged: Accuray, CyberKnife, radiation therapy, TomoTherapy, Varian | Leave a Comment »
Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: adjuvant, ADT, bicalutamide, CyberKnife, dutasteride, intermittent, pomegranate, SBRT, screening | 1 Comment »
Two posters presented today at the Genitourinary Cancers Symposium have extended our knowledge about outcomes after stereotactic body radiation therapy (SBRT or CyberKnife therapy) for localized disease.
Filed under: Diagnosis, Management, Treatment | Tagged: CyberKnife, outcome, SBRT, stereotactic body radiation therapy | 3 Comments »
A new article in Radiation Oncology provides initial 5-year outcomes of patients treated with stereotactic body radiation therapy (SBRT), also known as CyberKnife therapy.
Filed under: Management, Treatment, Uncategorized | Tagged: CyberKnife, outcome, SBRT, sterotactic body radiation therapy | 2 Comments »
Reuters has published a summary report on the discussions of a Medicare advisory panel (MedCAC) held yesterday to address the value of different types of radiation therapy in the treatment of early-stage prostate cancer.
Filed under: Management | Tagged: coverage, CyberKnife, Medicare, radiation | Leave a Comment »
Stereotactic body radiotherapy (SBRT) — aka CyberKnife radiotherapy — is among the most recent methods developed for the treatment of prostate cancer using radiation. People have been waiting a while now to see early data from a large series of patients.
Filed under: Management, Treatment | Tagged: CyberKnife, outcome, SBRT, stereotactic body radiotherapy | 2 Comments »
Today’s news reports include commentary on studies dealing with: Whether RALP outcomes are really comparable to those from RRP Surgical expertise, surgical caseload, and pelvic lymphadenectomy in treatment of intermediate- and high-risk prostate cancer Sexual function after first-line treatment with SBRT (CyberKnife) Distinguishing true biochemical recurrence from a PSA “bounce” after 125I-based prostate brachytherapy
Filed under: Management, Treatment | Tagged: bounce, CyberKnife, ED, failure brachytherapy, LRP, lymphadenextomy, outcomes, PSA, RALP, robot-assisted laparoscopic prostatectomy, SBRT, sexual function, stereotactic body radiotherapy | Leave a Comment »
Many readers will be interested in the article titled “Debate surrounds new prostate-cancer treatment” that appeared today in the Philadelphia Inquirer on the topic of prostate cancer treatment costs.
Filed under: Management, Treatment | Tagged: coverage, CyberKnife, radiotherapy | 5 Comments »
The ‘New” Prostate Cancer InfoLink has previously stated the importance of having more data about the potential of CyberKnife therapy in the treatment of localized prostate cancer. The first such data are now available.
Filed under: Management, Treatment | Tagged: CyberKnife, SBRT, stereotactic body radiation therapy | 5 Comments »
In the past year or so there have been three significant technological advances in the use of external beam radiotherapy for the treatment of localized prostate cancer, and we want to be sure that the patient community is both aware of and understands the limitations of these technological advances.
Filed under: Management, Treatment | Tagged: advances, Calypso, CyberKnife, external beam radiotherapy, outcome, RapidArc | 5 Comments »
An article in today’s New York Times addresses an issue of potentially growing importance for Medicare beneficiaries with prostate cancer. Is the form of treatment you want covered where you live?
Filed under: Management, Treatment | Tagged: CyberKnife, Medicare | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site